JP2019531764A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531764A5
JP2019531764A5 JP2019537049A JP2019537049A JP2019531764A5 JP 2019531764 A5 JP2019531764 A5 JP 2019531764A5 JP 2019537049 A JP2019537049 A JP 2019537049A JP 2019537049 A JP2019537049 A JP 2019537049A JP 2019531764 A5 JP2019531764 A5 JP 2019531764A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537049A
Other languages
English (en)
Japanese (ja)
Other versions
JP7224289B2 (ja
JP2019531764A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052808 external-priority patent/WO2018057802A1/en
Publication of JP2019531764A publication Critical patent/JP2019531764A/ja
Publication of JP2019531764A5 publication Critical patent/JP2019531764A5/ja
Priority to JP2023016697A priority Critical patent/JP2023058573A/ja
Application granted granted Critical
Publication of JP7224289B2 publication Critical patent/JP7224289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537049A 2016-09-21 2017-09-21 Cd123結合タンパク質並びに関連する組成物及び方法 Active JP7224289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023016697A JP2023058573A (ja) 2016-09-21 2023-02-07 Cd123結合タンパク質並びに関連する組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662397736P 2016-09-21 2016-09-21
US62/397,736 2016-09-21
US201762466192P 2017-03-02 2017-03-02
US62/466,192 2017-03-02
PCT/US2017/052808 WO2018057802A1 (en) 2016-09-21 2017-09-21 Cd123 binding proteins and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023016697A Division JP2023058573A (ja) 2016-09-21 2023-02-07 Cd123結合タンパク質並びに関連する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019531764A JP2019531764A (ja) 2019-11-07
JP2019531764A5 true JP2019531764A5 (OSRAM) 2020-12-17
JP7224289B2 JP7224289B2 (ja) 2023-02-17

Family

ID=61690646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537049A Active JP7224289B2 (ja) 2016-09-21 2017-09-21 Cd123結合タンパク質並びに関連する組成物及び方法
JP2023016697A Pending JP2023058573A (ja) 2016-09-21 2023-02-07 Cd123結合タンパク質並びに関連する組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023016697A Pending JP2023058573A (ja) 2016-09-21 2023-02-07 Cd123結合タンパク質並びに関連する組成物及び方法

Country Status (18)

Country Link
US (4) US11242400B2 (OSRAM)
EP (1) EP3515491A4 (OSRAM)
JP (2) JP7224289B2 (OSRAM)
KR (1) KR102559732B1 (OSRAM)
CN (1) CN109952112B (OSRAM)
AU (1) AU2017331256B2 (OSRAM)
BR (1) BR112019005333A2 (OSRAM)
CA (1) CA3037688A1 (OSRAM)
CO (1) CO2019003951A2 (OSRAM)
IL (1) IL265484B1 (OSRAM)
MX (2) MX2019003225A (OSRAM)
MY (1) MY194290A (OSRAM)
NZ (1) NZ751479A (OSRAM)
PH (1) PH12019500609B1 (OSRAM)
SG (1) SG10202102846SA (OSRAM)
UA (1) UA127450C2 (OSRAM)
WO (1) WO2018057802A1 (OSRAM)
ZA (1) ZA201902323B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
EP3515491A4 (en) 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
US11434297B2 (en) 2019-05-04 2022-09-06 Inhibrx, Inc. CD123-binding polypeptides and uses thereof
EP3753954A1 (en) * 2019-06-21 2020-12-23 Université de Franche-Comté Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells
US20220242962A1 (en) * 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
CN110804096B (zh) * 2019-11-21 2021-07-06 深圳普瑞金生物药业有限公司 Cd123单域抗体、核苷酸序列、表达载体及试剂盒
AU2021207470A1 (en) * 2020-01-13 2022-07-07 Aptevo Research And Development Llc Formulations for protein therapeutics
BR112022013730A2 (pt) * 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
CN111171155B (zh) * 2020-02-05 2021-02-19 北京智仁美博生物科技有限公司 抗cd3和cd123双特异性抗体及其用途
CN111732635B (zh) * 2020-06-22 2022-03-22 中国医学科学院基础医学研究所 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用
EP4232159A1 (en) * 2020-10-23 2023-08-30 Icahn School of Medicine at Mount Sinai Sars-cov-2 antibodies and uses thereof
KR20230117379A (ko) * 2020-12-01 2023-08-08 압테보 리서치 앤드 디벨롭먼트 엘엘씨 이종이량체 psma 및 cd3-결합 이중특이적 항체
MX2023009615A (es) * 2021-02-17 2023-08-24 Igm Biosciences Inc Moleculas de union anti-cd123 y usos de estas.
WO2022246244A1 (en) * 2021-05-21 2022-11-24 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
CN116162148B (zh) * 2021-11-24 2025-09-09 中山光度生物医药有限公司 多特异性配体结合分子及其应用
CN116836282B (zh) * 2023-02-13 2024-03-29 北京艺妙神州医药科技有限公司 抗体、嵌合抗原受体及其用途
CN117660325B (zh) * 2024-01-31 2024-04-19 苏州科为康生物医药科技有限公司 一种制备脐带血msc的培养基及其方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ES2176574T3 (es) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
EP1613262A2 (en) 2001-07-26 2006-01-11 The University of Utah Research Foundation In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation
CN103739706B (zh) * 2002-05-22 2015-11-18 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2550155C (en) * 2003-12-15 2015-03-17 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
EP1848672A4 (en) * 2005-02-01 2009-11-04 Morphosys Ag LIBRARIES AND METHOD FOR ISOLATING ANTIBODIES
AU2006247425A1 (en) * 2005-05-16 2006-11-23 Morphotek, Inc. Regulated vectors for selection of cells exhibiting desired phenotypes
SG163615A1 (en) 2005-07-11 2010-08-30 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US7949480B2 (en) 2006-06-14 2011-05-24 Simphotek, Inc. Method for determining an interaction between an electromagnetic radiation and a material
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
CA2695382A1 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of A fold-back diabody diphtheria toxin immunotoxin and methods of use
BRPI0919841A2 (pt) * 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
CN104558179A (zh) 2009-04-27 2015-04-29 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗IL-3Rα抗体
CA2771336C (en) 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
WO2012065161A2 (en) 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
CN104487587A (zh) * 2012-04-20 2015-04-01 新兴产品开发西雅图有限公司 Cd3结合多肽
EP4053162A1 (en) * 2012-05-18 2022-09-07 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
WO2014143807A2 (en) * 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
RS60305B1 (sr) 2014-09-05 2020-07-31 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3247725B1 (en) 2015-01-23 2020-07-01 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
CA2976360A1 (en) 2015-02-11 2016-08-18 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
WO2017053469A2 (en) * 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
EP3464365A1 (en) 2016-06-01 2019-04-10 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
EP3515491A4 (en) * 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
BR112022013730A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
AU2021207470A1 (en) 2020-01-13 2022-07-07 Aptevo Research And Development Llc Formulations for protein therapeutics

Similar Documents

Publication Publication Date Title
JP2019531764A5 (OSRAM)
JP2023058573A5 (OSRAM)
JP2015533853A5 (OSRAM)
JP2018531000A5 (OSRAM)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2016505556A5 (OSRAM)
FI3823664T3 (fi) Bispesifisiä anti-BCMA- x anti-CD3-vasta-aineita ja niiden käyttöjä
JP2020501531A5 (OSRAM)
JP2017149720A5 (OSRAM)
JP2018519263A5 (OSRAM)
JP2017535257A5 (OSRAM)
JP2018510617A5 (OSRAM)
JP2018503380A5 (OSRAM)
JP2017506067A5 (OSRAM)
HK1215035A1 (zh) 人源化抗cd134(ox40)抗體及其應用
JP2018521691A5 (OSRAM)
JP2016512223A5 (OSRAM)
JP2018513149A5 (OSRAM)
RU2014106671A (ru) Варианты гуманизированных иммуномодулирующих моноклональных антител
RU2017105915A (ru) Антитела против pd-1
JP2018520650A5 (OSRAM)
RU2013152960A (ru) Анти-cd40-антитела и способы применения
JP2016539096A5 (OSRAM)
JP2020530770A5 (OSRAM)
JP2019521098A5 (OSRAM)